デジタルバイオマーカー市場：タイプ別、治療分野別、用途別-2025-2030年の世界予測

デジタルバイオマーカー市場は、2023年に36億3,000万米ドルと評価され、2024年には43億4,000万米ドルに達すると予測され、CAGR 19.97％で成長し、2030年には130億米ドルに達すると予測されています。

デジタルバイオマーカーは、スマートフォン、ウェアラブル、その他の遠隔センサーなどのデジタル機器を通じて収集・測定される定量化可能な生理的、行動的、身体的データを指します。継続的かつリアルタイムなモニタリングを実現し、個別化医療や予防的な健康管理を可能にすることで、ヘルスケアの変革に重要な役割を果たします。デジタルバイオマーカーの必要性は、従来の方法よりも信頼性が高く、費用対効果が高く、包括的な洞察を提供できる可能性があることから生じています。製薬、バイオテクノロジー、ヘルスケアプロバイダー、学術研究などの分野で、疾病診断、治療モニタリング、健康管理への応用が進んでいます。主な最終用途には、慢性疾患管理、臨床試験、メンタルヘルス評価などがあり、患者データ収集の強化や転帰改善の恩恵を受けています。

市場成長は、デジタルヘルスにおける技術的進歩、慢性疾患の有病率の増加、個別化ヘルスケアソリューションに対する需要の高まりに大きく影響されます。さらに、人工知能と機械学習の台頭は、デジタルバイオマーカーデータの革新的な分析を促進し、実用的な洞察を提供しています。しかし、市場の拡大は、規制上の課題、データプライバシーに関する懸念、広範な検証と標準化の必要性などのハードルに直面しています。さらに、既存のヘルスケアシステムとの統合は、運用上の課題となる可能性があります。

様々なデジタルバイオマーカーを統合し、相互運用性とセキュリティを重視した一貫したヘルスケア戦略を実現する相互運用可能なプラットフォームの開発にはビジネスチャンスが存在します。企業はテクノロジー企業とのパートナーシップを活用し、データ分析機能を強化する一方で、ユーザーエクスペリエンスの向上を優先して採用を促進することができます。革新的な分野としては、センサーの精度向上、デジタル機器のコスト削減、新興国の未開拓市場の開拓などが挙げられます。さらに、学術機関との共同研究を活用することで、新たなバイオマーカーやアプリケーションの開発につなげることができます。継続的なイノベーションと戦略的プランニングにより、企業は複雑なデジタルバイオマーカーの状況を乗り切り、持続可能な成長を達成し、世界のヘルスケアの進歩に有意義な貢献をすることができます。

市場力学：急速に進化するデジタルバイオマーカー市場の主要市場インサイトを公開

デジタルバイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の治療におけるバイオマーカー検査の利用拡大
  • デジタルバイオマーカー診断の大きなメリット
  • デジタルバイオマーカーの患者中心の医薬品開発と精密医療への応用
• 市場抑制要因
  • バイオマーカー開発およびデジタルバイオマーカー採用に伴う高コスト
• 市場機会
  • 最近のデジタルバイオマーカーの進化による柔軟性とカスタマイズされた構成
  • 遠隔医療インフラへの政府投資
• 市場の課題
  • データ検証と解釈に関連する問題

ポーターのファイブフォース：デジタルバイオマーカー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：デジタルバイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、デジタルバイオマーカー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析デジタルバイオマーカー市場における競合情勢の把握

デジタルバイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスデジタルバイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、デジタルバイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨デジタルバイオマーカー市場における成功への道筋を描く

デジタルバイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の治療におけるバイオマーカー検査の利用増加
    • デジタルバイオマーカー診断の大きなメリット
    • 患者中心の医薬品開発と精密医療におけるデジタルバイオマーカーの応用
  • 抑制要因
    • バイオマーカーの開発とデジタルバイオマーカーの採用に関連する高コスト
  • 機会
    • より柔軟でカスタマイズされた構成を実現するデジタルバイオマーカーの最近の進歩
    • 遠隔医療インフラへの政府投資
  • 課題
    • データの検証と解釈に関連する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 デジタルバイオマーカー市場：タイプ別

• ハードウェア
  • センサー
  • ウェアラブルデバイス
• ソフトウェア

第7章 デジタルバイオマーカー市場治療領域別

• 心血管および代謝障害（CVMD）
• 筋骨格障害
• 神経疾患
• 精神疾患
• 呼吸器疾患
• 睡眠と運動の病気

第8章 デジタルバイオマーカー市場：最終用途別

• ヘルスケア消費者
• ヘルスケア提供者

第9章 南北アメリカのデジタルバイオマーカー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のデジタルバイオマーカー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのデジタルバイオマーカー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ActiGraph, LLC
• Adherium
• Akili, Inc.
• Altoida, Inc.
• Amgen Inc.
• Aural Analytics, Inc.
• Biofourmis Pte. Ltd.
• Biogen Inc.
• Brainomix
• Chugai Pharmaceutical Co., Ltd.
• Clarigent Health
• Eli Lilly and Company
• Empatica Inc.
• F. Hoffmann-La Roche Ltd.
• Feel Therapeutics
• GERO PTE. LTD.
• Huma Therapeutics Limited
• IXICO PLC
• Kinsa Inc.
• Koneksa Health
• Medable Inc.
• Owkin, Inc.
• Sidekick Health ehf.
• Verily Life Sciences
• VivoSense, Inc

LIST OF FIGURES

• FIGURE 1. DIGITAL BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. DIGITAL BIOMARKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIGITAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIGITAL BIOMARKERS MARKET DYNAMICS
• TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLE DEVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR AND METABOLIC DISORDERS (CVMD), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SLEEP & MOVEMENT DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE CONSUMERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 61. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 65. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 134. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 150. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 154. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 191. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

The Digital Biomarkers Market was valued at USD 3.63 billion in 2023, expected to reach USD 4.34 billion in 2024, and is projected to grow at a CAGR of 19.97%, to USD 13.00 billion by 2030.

Digital biomarkers refer to quantifiable physiological, behavioral, and physical data collected and measured through digital devices like smartphones, wearables, and other remote sensors. They play a critical role in transforming healthcare by providing continuous and real-time monitoring, enabling personalized medicine and proactive health management. The necessity of digital biomarkers arises from their potential to offer more reliable, cost-effective, and comprehensive insights than traditional methods. They are increasingly applied in disease diagnosis, treatment monitoring, and health management across sectors such as pharmaceuticals, biotechnology, healthcare providers, and academic research. Key end-use applications involve chronic disease management, clinical trials, and mental health assessments, which benefit from enhanced patient data collection and improved outcomes.

Market growth is significantly influenced by technological advancements in digital health, an increasing prevalence of chronic diseases, and a growing demand for personalized healthcare solutions. Furthermore, the rise of artificial intelligence and machine learning is driving innovative analytics of digital biomarker data, providing actionable insights. However, market expansion faces hurdles such as regulatory challenges, data privacy concerns, and the need for extensive validation and standardization. Additionally, integration with existing healthcare systems can pose operational challenges.

Opportunities exist in developing interoperable platforms that integrate various digital biomarkers into cohesive healthcare strategies, emphasizing interoperability and security. Businesses can capitalize on partnerships with technology companies to enhance data analytics capabilities, while prioritizing the enhancement of user experience to encourage adoption. Innovation areas include improving sensor accuracy, reducing costs of digital devices, and exploring untapped markets in emerging economies. Furthermore, leveraging collaborations with academic institutions for research can lead to the development of novel biomarkers and applications. With continuous innovation and strategic planning, companies can navigate the complex landscape of digital biomarkers to achieve sustainable growth and make meaningful contributions to global healthcare advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Digital Biomarkers Market

The Digital Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing usage of biomarkers testing for the treatment of chronic diseases
  • Significant benefits of digital biomarkers diagnosis
  • Applications of digital biomarkers in patient-focused drug development and precision medicine
• Market Restraints
  • High cost associated with biomarkers development and adoption of digital biomarkers
• Market Opportunities
  • Recent advancements in digital biomarkers for more flexibility and customized configuration
  • Government investment in telehealth infrastructure
• Market Challenges
  • Issues associated with data validation and interpretation

Porter's Five Forces: A Strategic Tool for Navigating the Digital Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Digital Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Digital Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Digital Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Digital Biomarkers Market

A detailed market share analysis in the Digital Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Digital Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Digital Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Digital Biomarkers Market

A strategic analysis of the Digital Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Digital Biomarkers Market, highlighting leading vendors and their innovative profiles. These include ActiGraph, LLC, Adherium, Akili, Inc., Altoida, Inc., Amgen Inc., Aural Analytics, Inc., Biofourmis Pte. Ltd., Biogen Inc., Brainomix, Chugai Pharmaceutical Co., Ltd., Clarigent Health, Eli Lilly and Company, Empatica Inc., F. Hoffmann-La Roche Ltd., Feel Therapeutics, GERO PTE. LTD., Huma Therapeutics Limited, IXICO PLC, Kinsa Inc., Koneksa Health, Medable Inc., Owkin, Inc., Sidekick Health ehf., Verily Life Sciences, and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Digital Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Hardware and Software. The Hardware is further studied across Sensor and Wearable Device.
• Based on Therapeutic Area, market is studied across Cardiovascular and metabolic disorders (CVMD), Musculoskeletal disorders, Neurological disorders, Psychiatric Disorders, Respiratory Disorders, and Sleep & Movement Disease.
• Based on End-Use, market is studied across Healthcare Consumers and Healthcare Providers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing usage of biomarkers testing for the treatment of chronic diseases
    • 5.1.1.2. Significant benefits of digital biomarkers diagnosis
    • 5.1.1.3. Applications of digital biomarkers in patient-focused drug development and precision medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with biomarkers development and adoption of digital biomarkers
  • 5.1.3. Opportunities
    • 5.1.3.1. Recent advancements in digital biomarkers for more flexibility and customized configuration
    • 5.1.3.2. Government investment in telehealth infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with data validation and interpretation
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Digital Biomarkers Market, by Type

• 6.1. Introduction
• 6.2. Hardware
  • 6.2.1. Sensor
  • 6.2.2. Wearable Device
• 6.3. Software

7. Digital Biomarkers Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Cardiovascular and metabolic disorders (CVMD)
• 7.3. Musculoskeletal disorders
• 7.4. Neurological disorders
• 7.5. Psychiatric Disorders
• 7.6. Respiratory Disorders
• 7.7. Sleep & Movement Disease

8. Digital Biomarkers Market, by End-Use

• 8.1. Introduction
• 8.2. Healthcare Consumers
• 8.3. Healthcare Providers

9. Americas Digital Biomarkers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Digital Biomarkers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Digital Biomarkers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ActiGraph, LLC
• 2. Adherium
• 3. Akili, Inc.
• 4. Altoida, Inc.
• 5. Amgen Inc.
• 6. Aural Analytics, Inc.
• 7. Biofourmis Pte. Ltd.
• 8. Biogen Inc.
• 9. Brainomix
• 10. Chugai Pharmaceutical Co., Ltd.
• 11. Clarigent Health
• 12. Eli Lilly and Company
• 13. Empatica Inc.
• 14. F. Hoffmann-La Roche Ltd.
• 15. Feel Therapeutics
• 16. GERO PTE. LTD.
• 17. Huma Therapeutics Limited
• 18. IXICO PLC
• 19. Kinsa Inc.
• 20. Koneksa Health
• 21. Medable Inc.
• 22. Owkin, Inc.
• 23. Sidekick Health ehf.
• 24. Verily Life Sciences
• 25. VivoSense, Inc